| Name | Title | Contact Details |
|---|
Tech Observer is a global Contract Research Organization (CRO) founded in 2005, with its headquarters in Paramus, New Jersey, and additional offices in New Delhi, Mumbai, and Singapore. The company specializes in clinical development support for the pharmaceutical, biotechnology, and medical device industries, extending its reach through local partners across the Asia-Pacific region. The company offers a comprehensive range of services that encompass the entire clinical research process. These include managing clinical trials, clinical data management, biostatistics and SAS programming, medical writing, post-marketing clinical studies, and staffing services. Tech Observer is ISO 9001:2008 and ISO 14155:2011 certified, demonstrating its commitment to quality and regulatory compliance. With a workforce of around 400 professionals, the company serves over 50 clients in more than 30 countries, focusing on various therapeutic areas such as oncology, cardiology, and infectious diseases. Tech Observer also emphasizes innovation with solutions like its AI-driven clinical trial risk tool, MyRBQM, and promotes diversity and professional growth within its team.
We serve as part-time or full-time interim CFOs, or work on a project basis to find solutions during periods of transition or critical need. Clients are typically closely held and/or managed, with our direction received from the CEO, owners, or the Board of Directors. We often work closely with executive managers to identify and resolve key issues and develop financial strategies supporting long term objectives.
Premia Managing Agency Limited ("PMAL") provides risk-transfer and run-off solutions for other Lloyds syndicates and capital providers. It is responsible for managing the run-off of Syndicate 1884 for the Year of Account 2018, following cessation of live market underwriting on 31 December 2018. PMAL is a subsidiary of Premia Holdings Ltd, a Bermuda based legacy reinsurance group with operations in the USA, Bermuda, UK and EU. PMAL is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.